Eukroma-KJ Cream Research Overview
Eukroma-KJ Cream 4%/2% is a dual-action dermatological formulation combining hydroquinone (4%) with kojic acid (2%) manufactured by Yash Pharma for in-vitro research applications. This professional-grade cream represents a sophisticated approach to studying melanin biosynthesis inhibition and tyrosinase enzyme activity in laboratory settings. Research scientists at Stroid UK Shop have access to this formulation for investigating cellular pigmentation mechanisms and melanocyte function studies. The compound’s dual-active design allows researchers to examine synergistic effects between established depigmenting agents in controlled experimental conditions.
Laboratory Research Applications
Researchers investigating melanogenesis pathways utilise this formulation to study the inhibitory effects on tyrosinase activity and melanin production in cellular models. The hydroquinone component acts as a phenolic compound that interferes with melanin synthesis at the enzymatic level, while kojic acid provides additional tyrosinase inhibition through metal chelation mechanisms. Scientists studying dermatological compounds examine this combination’s effects on melanocyte proliferation and differentiation in tissue culture systems. The cream’s formulation allows for topical application studies on skin explant models and examination of penetration kinetics through dermal barriers. Research teams investigating hyperpigmentation disorders analyse the compound’s effects on melanin distribution and cellular uptake mechanisms. Studies examining skin barrier function and cellular response to depigmenting agents benefit from this standardised formulation’s consistent active ingredient ratios.
Technical Specifications
| Parameter | Value |
|---|---|
| Active Ingredients | Hydroquinone 4%, Kojic Acid 2% |
| Manufacturer | Yash Pharma |
| Formulation Type | Topical Cream |
| Application | In-vitro research only |
| Storage | Room temperature, dry conditions |
| Research Grade | Laboratory standard |
Research Applications and Compliance
This formulation enables comprehensive studies of melanogenesis inhibition pathways and cellular response mechanisms in controlled laboratory environments. Research applications include investigating the synergistic effects of combined tyrosinase inhibitors and examining dose-response relationships in melanocyte culture systems. Scientists studying selective androgen receptor modulators and research peptides may incorporate dermatological studies into broader research protocols examining cellular signalling pathways. The standardised formulation ensures reproducible results across experimental conditions and enables comparative studies with other depigmenting agents. Research teams examine the compound’s effects on cellular viability, protein expression, and enzymatic activity in melanocyte populations. This product is manufactured exclusively for in-vitro research purposes and is not intended for human consumption, therapeutic use, or clinical applications. Researchers must ensure proper laboratory protocols and safety measures when handling this formulation in experimental settings.
